Progressive Patterns of Gifitinib Treating Advanced Non-small Cell Lung Cancer after Obtained Resistance
| Title: | Progressive Patterns of Gifitinib Treating Advanced Non-small Cell Lung Cancer after Obtained Resistance |
|---|---|
| Authors: | Bin WANG, Xin ZHANG, Lin LIN, Xuezhi HAO, Xiangru ZHANG, Junling LI, Yuankai SHI |
| Source: | Chinese Journal of Lung Cancer, Vol 16, Iss 10, Pp 510-513 (2013) |
| Publisher Information: | Chinese Anti-Cancer Association; Chinese Antituberculosis Association, 2013. |
| Publication Year: | 2013 |
| Collection: | LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| Subject Terms: | Gefitinib, Lung neoplsams, Resistance, Metastasis, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| More Details: | Background and objective Clinical observation was conducted on the resistance to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) gefitinib (Iressa) therapy for advanced non-small cell lung cancer (NSCLC) patients. Methods Ninety-three NSCLC patients in our hospital, showing effective or stable condition after 6-month previous gefitinib therapy, were included in this investigation. Among the patients, 94.6% of them were suffering from adenocarcinoma. The percentage of female is 79.6%; the percentage of non-smoking is 80.6%. During the therapy period, follow-up was preformed every 2 months. Results Among the 93 patients, median therapy time was 16 months (range: 8 to 70 months), and 21.5% (20/93) of them had received therapy for more than 2 years, while 8.6% (8/93) had received that for more than 3 years. The progression included 80% (72/90) for intrapleural progression, 38.9% (35/90) for primary tumor plus recurrence after sugary especially, 51.1% (46/90) for intrapulmonary metastasis, 25.6% (23/90) for pleural metastasis, 30% (30/90) for intracranial progression and 15.6% (14/90) for intraperitoneal progression. Conclusion Resistance to EGFR-TKI shows diversification in clinical observation, therefore, close clinical follow-up is necessary for early attention and timely treatment. |
| Document Type: | article |
| File Description: | electronic resource |
| Language: | Chinese |
| ISSN: | 1009-3419 1999-6187 |
| Relation: | https://doaj.org/toc/1009-3419; https://doaj.org/toc/1999-6187 |
| DOI: | 10.3779/j.issn.1009-3419.2013.10.02 |
| Access URL: | https://doaj.org/article/923a813313c64fd684118259be0ca58e |
| Accession Number: | edsdoj.923a813313c64fd684118259be0ca58e |
| Database: | Directory of Open Access Journals |
| ISSN: | 10093419 19996187 |
|---|---|
| DOI: | 10.3779/j.issn.1009-3419.2013.10.02 |
| Published in: | Chinese Journal of Lung Cancer |
| Language: | Chinese |